Integrating Emerging Therapies into the Treatment
Paradigm in the Management of Advanced
Renal Cell Carcinoma (RCC)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.


This activity is valid from January 15, 2017 to January 31, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by an educational grant from
Exelixis, Inc.

Description:
The prognosis for any treated renal cell cancer patient with progressing, recurring, or relapsing disease is poor, regardless of cell type or stage. Almost all patients with advanced renal cell cancer are incurable. The question and selection of further treatment depends on many factors, including previous treatment and site of recurrence, as well as individual patient considerations. Fortunately, clinicians have recently been equipped with more options to integrate into the advanced RCC treatment paradigm, including targeted therapies, which individualize therapy for patients with advanced RCC who have progressed on prior therapies, ultimately improving patient outcomes and quality of life. These new options have shown improved efficacy and safety in advanced RCC.

Upon Completion of this activity, participants will be able to:

  • Compare and contrast the safety, efficacy and mechanisms of action of emerging therapies in the management of advanced Renal Cell Carcinoma (RCC)

  • Review clinical data on newer therapies for patients with advanced RCC who have received at least one prior anti-angiogenic therapy

  • Analyze challenges clinicians encounter when managing advanced RCC and discuss evidence-based strategies to overcome these barriers

  • Discuss the role of tyrosine kinase inhibitors (TKIs) in the management of patients with advanced RCC

  • Examine proactive measures to manage and mitigate predictable treatment-related side effects in patients who are managed for advanced forms of RCC in multiple lines of care
     

Faculty: Daniel Geynisman, MD
Assistant Professor, Department of Hematology/Oncology
Fox Chase Cancer Center

Disclosure:

Dr. Geynisman serves in an advisory capacity to Pfizer and receives research support from Genentech/Roche, Merck and Millennium. He will be discussing unlabeled/investigational uses of Avelumab, Atezolizumab, Durvanlumab, and Pembrolizmab. His presentation has been peer reviewed.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This educational activity is supported by an educational grant from
Exelixis, Inc.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue